Table 5.
Patient profile receiving a 1st (2nd, 3rd, respectively) treatment versus patients receiving SCo
| 1st TX | SCo | 2nd TX | SCo | 3rd TX | SCo | |
|---|---|---|---|---|---|---|
| N = 1485 (%) | N = 229 (%) | N = 624 (%) | N = 66 (%) | N = 308 (%) | N = 34 (%) | |
| Age at diagnosis | ||||||
| Mean (years) | 58.6 | 74* | 58.3 | 70.1* | 58.7 | 66.1* |
| Median (years) | 57.6 | 76 | 58.2 | 71.0 | 57.8 | 65.0 |
| > 70 years | 22 | 71* | 8 | 50* | 8 | 41* |
| ECOG | ||||||
| PS0−1 | 85* | 35 | 85* | 11 | 82* | 12 |
| PS 2+ | 14 | 65* | 15 | 89* | 18 | 88* |
| Stage at diagnosis | ||||||
| Metastatic | 52 | 70* | 49 | 59 | 48 | 53 |
| Non-metastatic | 48* | 30 | 51 | 41 | 51 | 47 |
| Location of metastases | ||||||
| Bone only | 21 | 29* | 10 | 20* | 8 | 14 |
| Visceral ± bone | 68* | 44 | 71* | 45 | 66 | 52 |
| Cerebral ± others | 7 | 26* | 17 | 35* | 23 | 34 |
| Number of metastatic sites | ||||||
| 1 site | 46* | 39 | 27 | 28 | 24 | 22 |
| > site | 52 | 60* | 72 | 72 | 76 | 78 |
| Hormonal status | ||||||
| HR+ | 67 | 78* | 66 | 57 | 61 | 52 |
| HR− | 32* | 21 | 34 | 41 | 39 | 48 |
* Significant difference compared with comparator group, p < 0.05